Esteve CDMO, a global pure-play CDMO specialising in the development and manufacture of small-molecule APIs and pharmaceutical intermediates, is to spend $17.5 million on capacity expansion and containment capabilities at its Morton Grove, Illinois facility (USA), bringing total announced investment at the site to $33 million.
The new $17.5 million investment, in addition to the $15.5 million programme announced earlier this year, includes two new 500-gallon reactors, enhanced containment capabilities in the early-stage development laboratories, and a warehouse revamp. Together, these upgrades will increase flexibility in early development and expand manufacturing capacity as customer programmes progress toward larger clinical and commercial requirements.
Morton Grove site combines process R&D, analytical and stability testing, cGMP API manufacturing and CMC support, enabling pharmaceutical and biotech customers to seamlessly progress from early development into manufacturing.
The investment reinforces Esteve CDMO’s strategy to expand its US presence while connecting customers to its broader global development and manufacturing network.
